E 2730

Drug Profile

E 2730

Alternative Names: E2730

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Antiepileptic drugs
  • Mechanism of Action Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy
  • Preclinical Neurological disorders

Most Recent Events

  • 01 Jan 2017 Eisai initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03054194)
  • 01 Jan 2017 Phase-I clinical trials in Epilepsy in USA (PO)
  • 31 Oct 2016 Preclinical trials in Epilepsy in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top